The information on this website is being made available by Oxford Cannabinoid Technologies Holdings plc ("OCTH") in good faith and for information purposes only. Please read this notice carefully - it applies to all persons who view this Website. Please note that this notice may be altered or updated. You should therefore read it in full each time you visit this Website.

The information contained on this Website is not comprehensive and much of it is historical. No reliance may be placed for any purpose whatsoever on the, or the suitability of the shares of OCTH for any prospective investor and OCTH, its directors, shareholders, advisers, affiliates, agents, representatives and employees assume no responsibility to you or any third party for the consequences of any errors or omissions. Neither OCTH, its directors, shareholders, advisers, affiliates, agents, representatives nor employees accept any liability for any direct or indirect or consequential loss or damages of any kind resulting from any use of this Website or any information contained on it.

Some of the statements contained on this Website and in documents accessed through this Website may be forward looking statements. Actual results may differ from those expressed in such statements, depending on a variety of factors. The past performance of OCTH or its shares cannot be relied on as a guide to future performance. The price of the shares may go down as well as up and it may be that investors do not recoup the amount originally invested.

This Website and the information on it does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in OCTH, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied on in connection with or act as an inducement to enter into any contract or commitment therefor and any decisions you make based on the information contained on this Website are your sole responsibility having, where appropriate, taken independent advice as to the investment decision and any laws or regulations applicable to such investment decision.

The information contained in this section of the Website is not directed at, nor is it intended for access by, persons located or resident in the United States, Australia, Canada, the Republic of South Africa, or Japan or any other jurisdiction in which it may be unlawful to receive or view such information. If you are not permitted to view the information (or are in any doubt as to whether you are permitted to view the information), please exit this Website. Any shares of OCTH referred to in the information on this Website have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended. Such shares have also not been registered under the applicable securities laws of Australia, Canada, the Republic of South Africa or Japan and may not be offered or sold in Australia, Canada, the Republic of South Africa or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction.

OCTH, its directors, shareholders, advisers, affiliates, agents, representatives and employees (whether or not involved in creating, producing, maintaining or delivering this Website) exclude all liability and responsibility for any amount or kind of loss or damage that may result to you or a third party in connection with this Website in or the information contained on it.

By clicking "Accept" you accept you have read the terms of this Important Notice.

Accept Decline

Skip Navigation LinksHome   >   Investors   >   Business Model & Strategy

Business Model & Strategy

Business Model

OCT is a pharmaceutical company focused on the development of cannabinoid-based prescription medicines to target indications in the £42.5bn pain market, with regulatory marketing approval from agencies including the FDA1, EMA2 and MHRA3.

We have pursued a partnering model since it was established, with its highly experienced management team working closely with a range of carefully selected external academic and commercial partners. This includes an umbrella research collaboration agreement that was signed with the University of Oxford when OCT launched, and is continually evolving, with new partners engaged across the value chain to drive further research and development activities.


OCT aims to become a global leader in developing prescription medicines that target the endocannabinoid system and address significant unmet medical needs.

To achieve our aim, we use a drug development strategy that includes three inputs, in order to create a drug portfolio that balances risk, value and time to market, whilst ensuring market exclusivity around all of its key activities:

  • Unmodified natural compounds derived from cannabis (pCBs) and other cannabis-based compounds, targeting orphan indications.
  • Cannabinoid derivatives, which are pCBs that have been chemically modified through medicinal chemistry to improve physicochemical properties and drug-like characteristics.
  • Synthetic cannabinoids, or cannabinoid memetics, which are compounds that target cannabinoid receptors but are structurally distinct from pCBs. 

We have developed a proprietary library of 93 cannabinoid derivatives, which provides a source for further drug candidates to enter our pipeline. The library of compounds is screened by academic or commercial partners in disease model assays. The chemical modification of the cannabinoid creates a new compound with the potential for protection under composition of matter patents that we believe can be used by the Group to target common indications in addition to rare diseases.

Due to the highly patentable nature of OCT’s derivative compounds, we believe that a wide range of pain-related indications can be targeted by the Group. However, by employing an orphan indication strategy, OCT can also utilise unmodified pCBs and other off-patent compounds to target a group of rare diseases that would not otherwise be approached, and where exclusivity can be obtained. This provides the Group with a faster, less expensive path to commercialisation. Regulatory exclusivity is also granted to companies who develop drugs for these diseases. This market exclusivity allows natural unmodified pCBs to be developed as drug products for rare diseases.

We also intend to capitalise on a collaboration with a top-tier CRO to access a large and diverse chemical library (circa 400,000 compounds) and initiate a development programme aiming to identify a novel cannabinoid mimetic drug candidate targeting the ECS via an undisclosed receptor. This target has the potential to deliver therapeutic intervention in several neuropathic disorders, and also in other neurological, immune-inflammatory and oncology conditions. 

We may also in-licence any of the three types of compounds set out above. In-licensing drug candidates that have passed one or more stages in development provides the Group with an opportunity to advance its drug pipeline more quickly. In-licensing can also be used to diversify a drug pipeline and to target both large and orphan indications.

Company Information

OCT is incorporated under the laws of England and Wales under the Companies Act 2006 and the company number 13179529. The Company’s main country of operations is the United Kingdom, where it is headquartered.

1. Food and Drug Administration
2. European Medicines Agency
3. Medicines and Healthcare products Regulatory Agency